Top Stories News
Top Stories news
-
News Arena maps out its one-year plan for lorcaserin
Arena Pharmaceuticals and its partners at Eisai have had a chance to review exactly what the FDA wants to see on their experimental weight drug. -
News J&J investors fault board for ignoring 'red flags'
Some Johnson & Johnson ($JNJ) investors have resorted to court action, saying that directors and executives not only ignored 'red flags' that something was rotten within J&J, but allowed the company's once-stellar reputation to be destroyed. -
News Novartis aims Gilenya at advanced MS--and $5.4B
Novartis latest product, the multiple sclerosis treatment Gilenya, has already been hailed as a prospective blockbuster. -
News China plans 40% price cuts on key drugs
For the second time in two months, we're seeing reports that Chinese officials are planning to lower drug prices. -
News Novartis to plow $500M into Russia
Novartis' pledged to invest $500 million in Russian manufacturing, R&D and public health. -
News Big Pharma tops defense at government fraud
According to a new report, drugmakers defraud the federal government more than any other business. -
News Roche provides update on Avastin following reviews in Europe and the United States
Roche confirmed that following the reviews of Avastin (bevacizumab) in metastatic breast cancer by EMA) and FDA, the following regulatory announcements were made by the individual health authorities. -
News Cardinal Health today announced that the Federal Trade Commission has granted early termination of the waiting period under the
GE Healthcare today announced the expiration of the initial offering period of the previously announced tender offer by GE's wholly owned subsidiary, Crane Merger Sub, Inc.. -
News Indian pharma draws Chinese industry into trade pact
Indian drugmakers are aiming to team up with China in a bid to outpace western drugmakers who've been scrambling to grab market share in both countries. -
News EMA chief blasts $60B in wasted R&D spending each year
The outgoing chief of the European Medicines Agency concluded that the $85 billion the industry spends on drug R&D each year is simply wasted. -
News Glaxo Set to Re-Start Share Buyback
GlaxoSmithKline is splashing out UKpound162m on a protein drinks maker, but signalled that a lack of cheap takeover deals could see the drugs giant re-start its multi-billion pound share-buyback programme. -
News THE SAGE GROUP Reports that in 2010 Approximately 3 Million People in Western Europe Suffer from Critical Limb Ischemia
A recent analysis published by THE SAGE GROUP concluded that 3 million people in Western Europe have critical limb ischemia (CLI). -
News Bayer: 35 million Euros for the expansion of the development of biologicals
Bayer HealthCare is building a new facility center in Wuppertal on an area of some 1,000 square meters for the biotechnological production of pharmaceuticals to be used in clinical trials. -
News 36 Million Americans have Bought Medications Online Without a Doctor's Prescription
Illegal online drug sellers have provided tens of millions of Americans prescription medication via the Internet without a valid prescription, recent research has found. -
News Amgen trial success has analysts talking billions
New data shows that Xgeva (denosumab) delayed the spread of prostate cancer into bone, and that's set the oncology world abuzz. -
News India, EU patch up drug-transit dispute
Negotiators say India will withdraw its complaint filed at the World Trade Organization, now that it has reached an agreement with E.U. trade police. -
News Genzyme Reiterates Board's Position on Sanofi-Aventis Tender Offer
Genzyme Corp. today reiterated the unanimous recommendation of its board of directors. -
News Sanofi expected to extend Genzyme bid
Sanofi-Aventis' ($SNY) lowball bid for Genzyme ($GENZ) is set to expire at midnight tonight. -
News Medical Biotechnology Sector Grows Despite Economic Downturn
The BioIndustry Association welcomes the publication today of the latest government statistics highlighting the growth of the UK's innovative bioscience sector. -
News Russia favors domestic pharma with $3.9B
Russia has been rumbling at global pharma for awhile, but Prime Minister Vladimir Putin has sharpened his warnings to foreign drugmakers. -
News Sanofi almost beats Pfizer at M&A
Pharma M&A is up by 20 percent so far this year as drugmakers scramble to refill depleted pipelines, push into emerging markets and diversify beyond prescription drugs. -
News FDA panel supports approval of Orexigen's obesity drug
In what is likely to prove a shocker for many FDA watchers, the agency's expert advisors voted 13 to 7 in favor of approving Orexigen's obesity drug Contrave. -
News Merck KGaA Donation Program Supports Schistosomiasis Control in Africa
Merck KGaA is supporting the World Health Organization (WHO) in the fight against the neglected tropical disease schistosomiasis. -
News Bayer's Perspective on Innovation 2010
The Bayer Group aims to invest its resources as a whole more consistently in growth and innovation capability. 'We have a very successful record in innovation,' Management Board Chairman Dr. Marijn Dekkers said. -
News Public believe China and India set to become World leaders for innovation
China is set to become the world's powerhouse of innovation over the next decade, eclipsing the United States and Japan, according to an international survey released by AstraZeneca. -
News Roche, Baylor Research Institute Partner in Human Immunology Research
Focus on cancer vaccines, auto-immune disease diagnostics and treatment -
News Sanofi, Genzyme mull offer adjustments before Dec. 10 deadline
As time runs down on Sanofi-Aventis' $69-per-share offer for Genzyme --the offer expires Dec. 10--both sides are still far apart on an agreement. -
News New J&J recalls spawn worries of FDA action
The steady drumbeat of downbeat manufacturing news and recalls has heightened worries among market-watchers. -
News Genzyme Completes Sale of Genetic Testing Business to LabCorp
Genzyme Corporation has completed the sale of Genzyme Genetics to Laboratory Corporation of America Holdings for $925 million in cash. -
News Bristol-Myers Squibb and Alvin Ailey American Dance Theater Announce First-of-Its-Kind Collaboration
Bristol-Myers Squibb Company and Alvin Ailey American Dance Theater announced the launch of the 2011 REYATAZ? (atazanavir sulfate) 'Fight HIV Your Way' contest. -
News China advances price controls on foreign meds
China is working on a step-by-step reduction in drug prices that previously had been excused from the government's controls. -
News Law and order on the social media frontier
The New England Journal of Medicine is weighing in on social media. -
News Merck KGaA Announces Extension of FDA Priority Review Period for Cladribine Tablets
Merck KGaA announced that the U.S. Food and Drug Administration has extended its review period for Cladribine Tablets. -
News FDA Extends Priority Review of Cladribine in Relapsing MS
FDA extended the review to 'provide additional time for a full review of additional information provided under the new drug application.' -
News Abbott Named One of the Top 10 Companies in Calvert Diversity Survey
Abbott (NYSE: ABT) has been named one of the Top 10 companies for diversity in a new survey conducted by Calvert Group. -
News J&J pulls more children's drugs off store shelves
Johnson & Johnson ($JNJ) execs should write a blues song about recalls. -
News Stelmi to open a technical centre for innovation
Stelmi has created a technical centre at its headquarters near Paris, which will be operational early next year. -
News Honeyman to open pharma training facility
UK-based Honeyman Group will open a pharmaceutical training facility in February 2011. -
News 'Record' drug shortages include cancer meds
The FDA has released its latest list of scarce drugs, and several cancer drugs are included. -
News Privacy groups ask FTC to probe online marketing
Privacy advocates are asking the Federal Trade Commission to investigate how that information is used in drug marketing. -
News Roche dumps hep C development deal with Ligand
Roche is dropping a deal to develop new hepatitis C drugs with Ligand Pharmaceuticals, according to the UK biotech. -
News UCLA researcher targeted by animal rights activists
Animal rights activists have claimed responsibility for sending a package of razor blades to a UCLA researcher involved in animal studies. -
News Genzyme Successfully Meets First Milestones of FDA Consent Decree
Genzyme Corporation announced today that the company has ended fill/finish operations within its Allston plant for products sold in the United States, as required by the FDA consent decree. -
News Xention raises ?8m to fund drug development
UK biopharmaceutical firm Xention has raised ?8m in private equity funding to advance the development of drugs to treat atrial fibrillation. -
News WTO generics licensing system could prove useful
WHO has said the little-used World Trade Organisation (WTO) licensing system for generic medicines during health emergencies may actually become useful. -
News Roche announces implementation plans for its Operational Excellence Program
Roche disclosed the measures it plans to take as part of its Group-wide Operational Excellence Program, announced in September. -
News Europeans are Interested in Online Patient Education Programs
Half of Europeans using the Internet for health information are interested in online patient education programs from pharmaceutical companies. -
News UK government appoints life sciences business adviser
Chris Brinsmead, chairman of AstraZeneca Pharmaceuticals UK, has become the UK governments life sciences business adviser. -
News Journal of Clinical Lipidology Accepted for MEDLINE and PubMed by U.S. National Library of Medicine
The National Lipid Association announced the recent acceptance of its journal for indexing in PubMed and MEDLINE by the U.S. National Library of Medicine. -
News J&J, Takeda recall Velcade on particle fears
Johnson & Johnson has been hit with another recall, but this time J&J wasn't the company overseeing production. -
News Roche drops a bomb on the RNAi field
Roche singled out its work in RNAi when choosing its R&D targets for the budget axe, announcing plans to shutter the work underway in Kulmbach, Germany, Nutley, NJ and Madison, WI. -
News GSK: Not interested in Gemzyme deal
Despite rumors, GlaxoSmithKline's senior vice president of medicines discovery and development, says his company isn't considering a bid for Genzyme. -
News Amgen gets coveted cancer OK for denosumab
Approved as an osteoporosis treatment--sold under the brand name Prolia--the drug got the FDA nod for fracture prevention in certain cancer patients. -
News Cargill Announces Patent Application for Zerose Erythritol As an Orally Disintegrating Tablet Excipient
At CPHI Worldwide 2010, Cargill announced a new pharmaceutical patent application for Zerose? erythritol. -
News Paris Pharma Events Smash All Attendance Records
Attendees up by 14%,* Exhibitor Numbers Increase to 1934. -
News Benlysta review spooks investors ahead of FDA panel
Shares of Human Genome Sciences had been trimmed 11 percent as investors fretted over the implications of an FDA staff analysis of its lupus drug Benlysta. -
News FDA Approves New Treatment Option for Late-Stage Breast Cancer
The U.S. FDA approved Halaven to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease. -
News Deficit commission eyes Medicare drug rebates
For all the promise of tweaking the healthcare reform law in pharma-friendly ways, there's now a counterweight to those very plans. -
News Millions unite for diabetes awareness on World Diabetes Day 2010
Starting today, people from all corners of the world are uniting together for three days of celebration to put diabetes firmly in the public spotlight. -
News Roche's Avastin rejected by NICE for colon cancer
Roche has failed to get the cancer drug Avastin on the National Health Service formulary for colorectal-cancer treatment. -
News Bristol-Myers Squibb Foundation Launches $100 Million Initiative Targeting America's Type 2 Diabetes Crisis
Bristol-Myers Squibb Foundation launches $100 million initiative targeting America's type 2 diabetes crisis. -
News Nycomed is keeping the pace in third quarter 2010
Nycomed's strategy of focusing on emerging markets and specialty products is paying off. The third quarter results shows that the sales of Key Products and in emerging markets are continuing to help offset the impact from the loss of exclusivity of pan... -
News Advaxis Granted a Qualifying Therapeutic Discovery Project Credit Totaling $244,479 for Advaxis' Lead Construct Candidate ADXS11
Advaxis was awarded a Qualifying Therapeutic Discovery Project credit from the Federal Government for ADXS11-001. -
News Novartis teamed up with athletes for doctor marketing
Apparently, Novartis ($NVS) has done just that, using professional athletes as a draw at doctor dinners. -
News China Medicine Reports Third Quarter 2010 Financial Results
China Medicine Corporation today announced financial results for the third quarter ended September 30, 2010. -
News Hamburg aims to defend FDA from budget ax
FDA Commissioner Margaret Hamburg is trying to forestall any talk of cutting her agency's funding. -
News Laureate Pharma Launches New Regulatory Affairs Services and Appoints Robert G. Burford, Ph.D., as Vice President
Program to Provide Full Regulatory Support for Clients' Clinical Development Programs Under Experienced Leadership. -
News Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions
Sanofi-aventis has sent a letter to Genzyme Corporation requesting that Genzyme clarify its position on a number of potential Board actions raised in Genzyme's Schedule 14D-9. -
News PhRMA spent $25M on friendly lawmakers
PhRMA still has its eyes on healthcare reform.In fact, PhRMA spent some big bucks to back candidates who supported healthcare reform the first time around. -
News KOMBIGLYZE XR tablets approved in the US
The US Food and Drug Administration (FDA) approved KOMBIGLYZE? XR for the treatment of type 2 diabetes in adults. -
News Apricus Bio Awarded Three Qualifying Therapeutic Discovery Project Grants
Apricus Bio will use the proceeds of the grant funds to continue development of PrevOnco?, RayVa? and Femprox?. -
News Allergan plots Botox promo for migraine use
Allergan is gearing up to promote Botox as a migraine-fighter, a newly approved use for the wrinkle-fighting, muscle-relaxing drug. -
News China blesses Sanofi ($SNY) foray into OTC meds
Chinese officials gave the go-ahead to Sanofi-Aventis' ($SNY) joint venture with Hangzhou Minsheng Pharmaceutical Group. -
News Pharma can gain and lose from D.C. power shift
As healthcare and pharma experts are finding that the Washington power shift will present some new challenges. -
News Pfizer Reports Third-Quarter 2010 Revenues of $16.2 Billion
Pfizer Inc. reported financial results for third-quarter 2010. -
News In bombshell, DOJ reverses stance on gene patents
The U.S. Justice Department saying that unmodified DNA should not be patentable. -
News Waksal making big development plans for his new biotech venture
Waksal told that his new biotech company will be bigger and better than ImClone ever was. -
News Lipitor recall shares pallets, Puerto Rico with Tylenol, Glumetza
This time driving a Pfizer recall of the cholesterol-fighting blockbuster Lipitor. -
News Drugmakers rack up $1B in small deals
Drugmakers may be focusing on smaller deals this year, rather than the megamergers of 2009, but those smaller buys do add up. -
News Big Pharma backs tropical disease plan
The World Health Organisation (WHO) says four major medicine companies are backing an initiative to boost the flow of pharmaceuticals fighting lower profile tropical diseases. -
News GSK and Amicus Therapeutics sign exclusive agreement
UK pharmaceutical manufacturer GlaxoSmithKline (GSK) has licensed a treatment for Fabry disease from Amicus Therapeutics. -
News GSK to pay $750M over adulterated drugs
GlaxoSmithKline and its subsidiary SB Pharmco have agreed to pay $750 million to resolve criminal and civil allegations relating to the manufacturing and sale of certain adulterated drugs. -
News U.K. earmarks £200M for NICE-rejected drugs
The government has set up an annual fund of ?200 million per year through 2014 to financerejected drugs . -
News BMS aims for new inspection of troubled plant
Bristol-Myers Squibb officials promise that they're scrambling to fix 'significant' problems at a Puerto Rico plant. -
News Intellectual Property Concerns and Domestic Bias Hold Back Research and Development in Asia-Pacific
Latest figures, released by MedTRACK, a biomedical database of Life Science Analytics, show stagnant product development across the Asia Pacific (APAC) region. -
News Targeting the untreatable
Some health conditions still have no treatments while the drugs invented to treat others are less effective than they might be. Dr Sarah Houlton describes the recent efforts of medicinal chemists to address these challenges. -
News Abraxis deal done, Celgene eyes cancer franchise
Celgene has wrapped up its $3 billion-plus buyout of Abraxis BioScience. -
News After FDA's ARNA decision, what's next for obesity drugs?
The FDA's decision to reject Arena Pharmaceuticals' application for lorcaserin raises the stakes for two other companies looking for approval for their weight-loss drugs. -
News UK initiatives to speed up delivery of medicines to patients
UK Science Minister David Willetts and Health Minister Lord Howe have launched an initiative to boost partnership between academics, clinicians and the life sciences industry. -
News New migraine use for Botox could be worth $1B
The FDA finally approved Allergan wrinkle-fighter Botox as a treatment for migraines. -
News GSK: Feds, states launch Avandia probes
The Avandia mess weighed on GlaxoSmithKline's third-quarter earnings, that's now a matter of record. -
News Sanofi raises big loan as it plots Genzyme buyout strategy
Sanofi says that regulators have given the company a green light to proceed with its $18.5 billion buyout bid. -
News Cost Benefits and Scientific Expertise Provide China Strategic Ad
China has the advantages of scientific expertise and comprehensive infrastructure, which are critical for drug discovery activities. -
News BASF expects record year in 2010
BASF has lifted its profit outlook for the full year after reporting strong third-quarter sales. -
News Should long-term drugs get greater scrutiny?
Drugs for these chronic diseases present a novel set of challenges about how to assess their safety. -
News Manufacturing Safety Raises Concern
Last week, pharmaceutical heads met as a result of a drugs recall after a pill mix up of breast cancer pills. -
News Xarelto and Firazyr Top UK Prix Galien Awards
A drug that could herald the disappearance of warfarin clinics in the UK has won the 2010 UK Prix Galien Innovative Product Award. -
News PharmOptima Appoints Director of Business Development
PharmOptima, LLC, is pleased to announce the appointment of Rick Coulon as Director of business development. -
News J&J, Merck postpone Remicade ruling to 2011
We won't find out what happens to Merck's disputed Remicade rights until next year. -
News VC investing declines in Q3, but biotech sees bump
While Venture capital investments declined sharply in the third quarter of 2010, Biotechnology continued to bring in significant funding. -
News Operation Pangea III cracks down on illegal online drugs
Forty-five countries took part in Operation Pangea III this month, which resulted in 76 people either being arrested or placed under investigation. In total 290 online pharmacies selling fake and illegal drugs were shut down. -
News Pfizer checkmates King
Pfizer Inc.and King Pharmaceuticals have entered into a definitive merger agreement. Pfizer will acquire King, a diversified specialty pharmaceutical discovery and clinical development company, for $3.6 billion in cash, or $14.25 per share. -
News Investors ask judge to force Genzyme to the bargaining table
Some Genzyme investors aren't willing to wait and see if the Big Biotech's board can be gradually lured to the bargaining table by Sanofi's slow motion M&A tactics. -
News Advisory panel rejections carry the greatest clout at the FDA
The FDA is far more likely to be influenced by a rejection than an approval. -
News China proposes boost to supply chain security
The Chinese government appears to be stepping up its efforts to fight the contamination and fakery that have sullied its reputation as a drug supply source. -
News Report: Officials wrongly closed Indian vax plants
A report by an investigating committee finds that top Ministry officials made the call. The report states the decision to close the three plants. -
News Big Pharma, Soros in emerging-markets deals
Some big names have cropped up in a new round of emerging-markets investments. -
News UCB and Synosia Therapeutics Sign Strategic Alliance in Neurology
UCB and Synosia Therapeutics announced today a new strategic partnership in neurology. -
News Novartis signs commitment with WHO to provide leprosy drugs
Novartis has agreed with the World Health Organization (WHO) to continue its efforts to eliminate leprosy. -
News Indena Wins Best New Product Award
Meriva has been elected 'Best New Product'of the year by the judging panel of the European Outsourcing Awards. -
News BREAKING NEWS: Sanofi cuts 1,700 U.S. jobs
Sanofi-Aventis announced that it's restructuring its U.S. pharmaceutical operations. -
News Abbott pulls Meridia in multiple markets
The FDA Abbott Laboratories is voluntarily withdrawing Meridia from the U.S. market following concerns that the drug may increase risk of serious cardiovascular events in patients with heart problems. In addition, the company is pulling the drug from... -
News Sanofi-Genzyme parley brews more conflict
Genzyme's board officially nixed Sanofi-Aventis' hostile bid for the company.But the back-and-forth between the two companies is increasingly tense. -
News Is musty Lipitor recall pallet-related like J&J's?
Pfizer has recalled 10 lots of the cholesterol drug, citing a 'musty odor' in some bottles of tablets made by a contract manufacturer. -
News China to fuel bigger pharma growth in 2011
Drug market of China is projected to grow 25 percent to 27 percent to more than $50 billion, to become the world's third-largest pharma market. -
News Pharma protests Indian licensing proposal
Indian regulators have been considering all sorts of measures to protect homegrown drugmakers,Understandably, international drugmakers don't like the idea. -
News Nanotechnology brings personalized therapy 1 step closer to reality
A novel technology can make nanoscale protein measurements, which scientists can use in clinical trials to learn how drugs work -
News Facing Taxotere loss, Sanofi mulls Genzyme bid
The juxtaposition of Sanofi-Aventis headlines today is telling. -
News Chief Justice unloads Pfizer shares
A couple of juicy pharma cases are coming up at the Supreme Court, so Chief Justice John Roberts has unloaded his Pfizer stock and is now ready to take part. -
News Incoming Bayer chief eyes $23B in deals
Bayer's incoming CEO Marijn Dekkers told reporters that he's prepared to spend up to $23 billion to beef up the company's healthcare business.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance